Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

BACKGROUND: Boceprevir and telaprevir have recently showed dramatically better treatment outcomes than conventional PEGylated interferon plus ribavirin for the treatment of hepatitis C virus genotype 1, but the average cost per patient is unknown. METHODS: In the UK context, we performed a budget im...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Thorlund, Kristian, Druyts, Eric, El Khoury, Antoine C, Mills, Edward J
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2012
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3503472/
https://ncbi.nlm.nih.gov/pubmed/23180971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S37205
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki